SKIN & AESTHETICS RESEARCH / COLOPHON
About This Casebook
A briskly clinical, citation-anchored casebook on the skin-remodeling and pigmentation-peptide literature — GLOW and Melanotan II. Nothing sold, no one treated, no advice given.
What this casebook keeps
Peptide Rejuvination keeps a casebook on two peptides studied for aesthetic rejuvenation and pigmentation: GLOW, a multi-peptide skin- and tissue-repair blend, and Melanotan II, a melanocortin receptor agonist, with GLOW leading the file.
Every entry is written like a clinical note rather than a sales page: what the compound is, what the evidence actually shows, what to watch for, and what is still open. GLOW's entry splits into three separate constituent literatures, because that is all the evidence there is — no study has tested the blend as formulated. Melanotan II's entry sets a small, dated controlled-trial base against a growing case-report record, because that is the honest state of its file too.
Neither compound is an approved medicine. GLOW's constituents run from a legal cosmetic ingredient (topical GHK-Cu) to unapproved, WADA-prohibited research chemicals (BPC-157, TB-500). Melanotan II has never finished clinical development for any indication. Both are worked to the same standard: record what was studied, in what model, and what was found — and mark plainly where the evidence stops.
How the notes are kept
Three rules keep the casebook honest. First, every research claim carries a numbered citation — peer-reviewed journal articles and case reports, with DOIs and PubMed links, collected on the references page. When a finding is a case report rather than a controlled trial, or an animal or cell model rather than human data, that distinction is written down, not smoothed over.
Second, each entry is graded at its actual strength. A single 10-person crossover trial from 1998 is logged as exactly that, never inflated into a blanket safety claim; a 2026 case report of self-administered dosing is logged as one documented instance, not a population-level rate.
Third, what users report is filed well apart from what studies found. Where GLOW or Melanotan II users describe an effect in online write-ups, that material is labeled anecdotal right on the page and is never dressed as though it came from a controlled study. Keeping those two apart is the strictest rule in the casebook, precisely because supplier marketing for both compounds blurs it so often.
What the casebook won't do
Peptide Rejuvination is no pharmacy, clinic, supplier, or broker for any peptide or research chemical. It does not sell or source GLOW, Melanotan II, or any of their constituents, and it holds no referral or affiliate tie to any supplier. It diagnoses no skin condition, recommends no cosmetic procedure, and prescribes nothing.
No dose, schedule, or route is put forward for any person. Where a dose appears in these notes, it is there because a cited study or case report used it — never as a suggestion from the casebook.
Anyone seeking dermatological or medical guidance should consult a licensed clinician in their own jurisdiction. Notes on citation fixes, newly published studies, or stale references are welcome by way of the contact page; that mail is read, but requests for medical advice can't be answered.